13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0000200406
Total reported value
$761.7M
$761.7M
15 檔
93.1%
In Q2 2026, Johnson & Johnson's U.S. equity holdings reached a combined market value of $761.7M, distributed across 15 disclosed stock positions.
In Q2 2026, Johnson & Johnson adopted a defensive or profit-taking posture, trimming 0 positions and completely liquidating 2 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including PTGX, NBTX, MGTX) accounted for 93.1% of total reported equity market value during Q2 2026.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 37.59% | +7.71% | — | |
| 2 | NBTX | Nanobiotix SA - Adr | Stock-Other | 26.55% | -3.54% | — | |
| 3 | MGTX | MeiraGTx Holdings plc | Stock-Other | 11.23% | -1.64% | — | |
| 4 | RAPP | Rapport Therapeutics Inc | Stock-Other | 9.31% | -1.44% | — | |
| 5 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 4.06% | -0.57% | — | |
| 6 | LEGN | Legend Biotech Corp-adr | Stock-Other | 2.95% | -0.82% | — | |
| 7 | CVRX | Cvrx Inc | Stock-Other | 2.59% | -1.67% | — | |
| 8 | XNCR | Xencor Inc | Stock-Other | 1.51% | +0.94% | — | |
| 9 | ✓ | Stock-Other | 1.48% | +1.52% | — | ||
| 10 | FATE | Fate Therapeutics Inc | Stock-Other | 1.14% | -0.09% | — | |
| 11 | PRCT | Procept Biorobotics CORP | Stock-Other | 1.01% | -0.15% | — | |
| 12 | NMRA | Neumora Therapeutics Inc | Stock-Other | 0.39% | -0.25% | — | |
| 13 | VOR | Vor Biopharma Inc | Stock-Other | 0.12% | +0.01% | — | |
| 14 | LAB | Standard Biotools Inc | Stock-Other | 0.03% | — | — | |
| 15 | ACET | Adicet Bio Inc | Stock-Other | 0.02% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | MGTX | MeiraGTx Holdings plc | +2.4% | — | Unchanged |
| 2 | ✓ | +1.5% | NEW | New buy | |
| 3 | RAPP | Rapport Therapeutics Inc | +0.8% | — | Unchanged |
| 4 | LEGN | Legend Biotech Corp-adr | +0.7% | — | Unchanged |
| 5 | FATE | Fate Therapeutics Inc | +0.5% | — | Unchanged |
| 6 | XNCR | Xencor Inc | +0.1% | — | Unchanged |
| 7 | CTNM | Contineum Therapeutics Inc-a | +0.1% | — | Unchanged |
| 8 | ACET | Adicet Bio Inc | — | — | Unchanged |
| 9 | LAB | Standard Biotools Inc | 0% | — | Unchanged |
| 10 | NNOX | Nano-X Imaging Ltd. | 0% | EXIT | Sold out |
| 11 | VOR | Vor Biopharma Inc | 0% | — | Unchanged |
| 12 | NBTX | Nanobiotix SA - Adr | -0.1% | — | Unchanged |
| 13 | NMRA | Neumora Therapeutics Inc | -0.2% | — | Unchanged |
| 14 | RLYB | Rallybio CORP | -0.2% | EXIT | Sold out |
| 15 | PRCT | Procept Biorobotics CORP | -0.4% | — | Unchanged |
| 16 | PTGX | Protagonist Therapeutics Inc | -2% | — | Unchanged |
| 17 | CVRX | Cvrx Inc | -3.3% | — | Unchanged |
According to official SEC Form 13F filings, Johnson & Johnson reported a total U.S. public equity portfolio value of $761.7M across 15 disclosed positions in Q2 2026.
During Q2 2026, Johnson & Johnson's top holdings by market value included PTGX (37.6%)、NBTX (26.6%)、MGTX (11.2%). The largest single position, PTGX, represented 37.6% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
市值: $11.8M
Top Position Liquidated / Trimmed
RLYB
前期市值: $1.4M
In Q2 2026, Johnson & Johnson made 3 total portfolio adjustments, initiating 1 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 2 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.